SavedAdd your journal

Journals / Journal of the Turkish-German Gynecological Association / 2017 / Cilt: 18 - Sayı: 3

Revaluating the survival effects of International Federation of Gynecology and Obstetrics 1988 stage IIIA criteria for endometrial cancer

Taner TURAN
Derman BAŞARAN
Işın ÜREYEN
Alper KARALOK
Osman TÜRKMEN
Günsu KİMYON
Gizem KUL
Gökhan TULUNAY
Pages
110–115
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In patients with stage IIIA EC according to the FIGO 1988 staging system, only uterine serosal involvement was related with adverse oncologic outcomes, not adnexal involvement or presence of positive cytology. (J Turk Ger Gynecol Assoc 2017; 18: 110-5)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to define factors that affected survival in the International Federation of Gynecology and Obstetrics (FIGO) 1988 stage IIIA endometrial cancer (EC).
📊
Key Findings & Data:Material and Methods: The study included patients with EC who underwent surgery between 1992 and 2013.
💡
Conclusion & Impact:Conclusion: In patients with stage IIIA EC according to the FIGO 1988 staging system, only uterine serosal involvement was related with adverse oncologic outcomes, not adnexal involvement or presence of positive cytology. (J Turk Ger Gynecol Assoc 2017; 18: 110-5)
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: This study aimed to define factors that affected survival in the International Federation of Gynecology and Obstetrics (FIGO) 1988 stage IIIA endometrial cancer (EC). Material and Methods: The study included patients with EC who underwent surgery between 1992 and 2013. Patients with adnexal metastases, uterine serosal involvement or positive peritoneal cytology (stage IIIA disease according to the former 1988 FIGO staging system) were selected for further analysis. Clinical and pathologic factors associated with progression-free survival (PFS) were evaluated using univariateand multivariate statistical tests. Results: Seventy-seven patients with stage IIIA disease according to the 1988 FIGO staging system were included. The median follow-up was 37 months (range, 1-175 months) and recurrence was detected in 19 patients. Univariate analysis revealed that the presence of uterine serosal invasion and advanced histologic grade (grade 1-2 vs. grade 3) were associated with diminished PFS (p=0.001, p=0.047). The presence of adnexal involvement and positive peritoneal cytology had no statistically significant influence on PFS (p=0.643 and p=0.795, respectively). Conclusion: In patients with stage IIIA EC according to the FIGO 1988 staging system, only uterine serosal involvement was related with adverse oncologic outcomes, not adnexal involvement or presence of positive cytology. (J Turk Ger Gynecol Assoc 2017; 18: 110-5)

🔖

Cite This Article

TURAN, T., BAŞARAN, D., ÜREYEN, I., KARALOK, A., TÜRKMEN, O., KİMYON, G., KUL, G., TULUNAY, G. (2022). Revaluating the survival effects of International Federation of Gynecology and Obstetrics 1988 stage IIIA criteria for endometrial cancer. Journal of the Turkish-German Gynecological Association, Cilt: 18 - Sayı: 3, 110–115. https://ajindex.com/articles/567525

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Slomovitz BM, Ramondetta LM, Lee CM, Oh JC, Eifel PJ, Jhingran A, et al. Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy. Int J Gynecol Cancer 2005; 15: 510-6.
  2. Garg G, Gao F, Wright JD, Hagemann AR, Zighelboim I, Mutch DG, et al. The risk of lymph node metastasis with positive peritoneal cytology in endometrial cancer. Int J Gynecol Cancer 2013; 23: 90-7.
  3. Milgrom SA, Kollmeier MA, Abu-Rustum NR, Makker V, Gardner GJ, Barakat RR, et al. Positive peritoneal cytology is highly predictive of prognosis and relapse patterns in stage III (FIGO 2009) endometrial cancer. Gynecol Oncol 2013; 130: 49-53.
  4. Obermair A, Geramou M, Tripcony L, Nicklin JL, Perrin L, Crandon AJ. Peritoneal cytology: impact on disease-free survival in clinical stage I endometrioid adenocarcinoma of the uterus. Cancer Lett 2001; 164: 105-10.
  5. Kashimura M, Sugihara K, Toki N, Matsuura Y, Kawagoe T, Kamura T, et al. The significance of peritoneal cytology in uterine cervix and endometrial cancer. Gynecol Oncol 1997; 67: 285-90.
  6. Descamps P, Calais G, Moire C, Bertrand P, Castiel M, Le Floch O, et al. Predictors of distant recurrence in clinical stage I or II endometrial carcinoma treated by combination surgical and radiation therapy. Gynecol Oncol 1997; 64: 54-8. WHO handbook for reporting results of cancer treatment. WHO Offset Publication; 1979: 148. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet 2009; 105: 103-4.
  7. Preyer O, Obermair A, Formann E, Schmid W, Perrrin LC, Ward BG, et al. The impact of positive peritoneal washing and serosal and adnexal involvement on survival in patients with stage IIIA uterine cancer. Gynecol Oncol 2002; 86: 269-73.
  8. Grimshaw RN, Tupper WC, Fraser RC, Tompkins MG, Jeffrey JF. Prognostic value of peritoneal cytology in endmetrial carcinoma. Gyecol Oncol 1990; 36: 97-100.
  9. Kasamatsu T, Onda T, Katsumata N, Sawada M, Yamada T, Tsunematsu R, et al. Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus. Br J Cancer 2003; 88: 245-50.
  10. Saga Y, Imai M, Jobo T, Kuramoto H, Takahashi K, Konno R, et al. Is peritoneal cytology a prognostic factor of endometrial cancer confined to the uterus? Gynecol Oncol 2006; 103: 277-80.
  11. Garg G, Gao F, Wright JD, Hagemann AR, Mutch DG, Powell MA. Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. Gynecol Oncol 2013; 128: 77-82.
  12. Konski A, Poulter C, Keys